Modag Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$3.46M
- Investors
-
8
Modag General Information
Description
Developer of a biotechnology platform designed to focus on the research and development of therapeutics and diagnostics for neurodegenerative diseases. The company's platform helps to bind cells to a structural epitope specific for pathological disease-related oligomers and inhibits their neurotoxic properties, enabling physicians to have access to an oligomer modulator for multiple system atrophy and other synucleinopathies.
Contact Information
Website
www.modag.netCorporate Office
- Mikroforum Ring 3
- 55234 Wendelsheim
- Germany
Corporate Office
- Mikroforum Ring 3
- 55234 Wendelsheim
- Germany
Modag Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 05-Aug-2020 | $3.46M | Completed | Clinical Trials - Phase 1 | ||
| 3. Later Stage VC (Series A) | 27-May-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 01-Jan-2015 | $1.26M | $3.28M | Completed | Stealth | |
| 1. Seed Round | 01-Jan-2013 | $3.28M | $3.28M | Completed | Stealth |
Modag Comparisons
Industry
Financing
Details
Modag Competitors (2)
One of Modag’s 2 competitors is Biohaven, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biohaven | Formerly VC-backed | New Haven, CT | ||||
| Neuropore Therapies | Corporation | San Diego, CA |
Modag Patents
Modag Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4682539-A1 | Method for detecting misfolded alpha-synuclein protein in biological samples to determine the presence of synucleinopathies in an individual | Pending | 15-Jul-2024 | ||
| WO-2026017679-A1 | Method for detecting misfolded alpha-synuclein protein in biological samples to determine the presence of synucleinopathies in an individual | Pending | 15-Jul-2024 | ||
| AU-2023227368-A1 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use | Pending | 01-Mar-2022 | ||
| EP-4486340-A1 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use | Pending | 01-Mar-2022 | ||
| US-20250161273-A1 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use | Pending | 01-Mar-2022 | A61K31/4155 |
Modag Signals
Modag Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Parkinson's UK | Corporation | |||
| Massa Investment Group | Real Estate | Minority | ||
| Max-Planck-Gesellschaft | Corporation | Minority | ||
| Michael J. Fox Foundation | Limited Partner | |||
| Bayerische Patentallianz | Corporation | Minority |
Modag FAQs
-
When was Modag founded?
Modag was founded in 2013.
-
Where is Modag headquartered?
Modag is headquartered in Wendelsheim, Germany.
-
What is the size of Modag?
Modag has 15 total employees.
-
What industry is Modag in?
Modag’s primary industry is Biotechnology.
-
Is Modag a private or public company?
Modag is a Private company.
-
What is Modag’s current revenue?
The current revenue for Modag is .
-
How much funding has Modag raised over time?
Modag has raised $16.7M.
-
Who are Modag’s investors?
Parkinson's UK, Massa Investment Group, Max-Planck-Gesellschaft, Michael J. Fox Foundation, and Bayerische Patentallianz are 5 of 8 investors who have invested in Modag.
-
Who are Modag’s competitors?
Biohaven and Neuropore Therapies are competitors of Modag.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process